Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy

Background: Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the ‘mixed responses’ frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resistant to targeted therapy, whereas more differentiated MITF+ tumor cells do respo...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	M. Willemsen, J. Bulgarelli, S.K. Chauhan, R.R. Lereim, D. Angeli, G. Grisendi, G. Krebbers, I. Davidson, J.A. Kyte, M. Guidoboni, R.M. Luiten, W.J. Bakker
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2024-12-01
Saila:	Immuno-Oncology and Technology
Gaiak:	melanoma AXL MITF DC vaccination immune checkpoint tumor heterogeneity
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S259001882400306X
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!